Skip to main content
. Author manuscript; available in PMC: 2010 Aug 25.
Published in final edited form as: Oncogene. 2009 Nov 30;29(8):1238–1248. doi: 10.1038/onc.2009.410

Figure 1. Lapatinib treatment inhibits the NF-κB and PI3K pathways in Her2-overexpressing cells.

Figure 1

A) Western blot of phospho-p65S536 in multiple breast cancer cell lines treated with lapatinib. Breast cancer cell lines were treated with 1 μM dual EGFR/Her2 inhibitor lapatinib or DMSO vehicle control for 12 hours. Western blots were performed with 25 μg protein from whole cell extracts. B) Western blot of phospho-IκBαS32/36 in SKBr3 cells treated with lapatinib. SKBr3 cells were treated with lapatinib (1 μM) or DMSO control over a course of 24 hours and levels of phospho-IκBαS32/36 were measured by western blot of 25 μg total protein from whole cell extracts. C) Western blot of phospho-AktS473 in SKBr3 cells treated with lapatinib. SKBr3 cells were treated for 12 hours with dual EGFR/Her2 inhibitor lapatinib and levels of phospho-AktS473 were measured by western blot of 25 μg protein from whole cell extracts.